Objective: To assess ethnic differences in disease control, exacerbations, biological phenotype and treatment in UK severe asthma.
Methods: We compared demographics, type-2 biomarkers, lung function, asthma control, medications and healthcare utilisation between White and ethnic minority group [EMG] patients in the UK Severe Asthma Registry (UKSAR) and Optimum Patient Care Research Database (OPCRD).
Results: 3,637 patients (665 EMG) were included from UKSAR and 10,549 (577 EMG) from OPCRD. EMG patients had higher levels of uncontrolled disease when measured using the asthma control questionnaire in UKSAR (OR:1.47, 95%CI: 1.12-1.93) and the Royal College of Physicians 3 Questions in OPCRD (OR:1.82, 95%CI: 1.27-2.60). Although exacerbation rates were similar, EMG patients were more likely to have recently attended ED (OR:1.55, 95%CI: 1.26-1.92) or been hospitalised (OR:1.31, 95% CI: 1.07-1.59) due to their asthma. Inflammatory biomarkers were consistently higher in EMG severe asthma including blood eosinophils in OPCRD (Ratio:1.12, 95%CI: 1.05-1.20) and in UKSAR blood eosinophils (Ratio:1.16, 95%CI: 1.06-1.27), FeNO (Ratio:1.14, 95%CI: 1.04-1.26) and IgE (Ratio:1.70, 95%CI: 1.47-1.97). EMG patients were more likely to be atopic in the UKSAR (OR:1.32; 95%CI: 1.07-1.63) and OPCRD (OR:1.67; 95%CI: 1.26-2.21), and less likely to be using maintenance oral corticosteroids at referral (OR:0.75 [95%CI: 0.61-0.92]).
Conclusions: Severe asthma patients from EMGs presented with higher disease burden and were more likely to attend ED. They had a distinct phenotypic presentation, and differences in medicine utilisation, with higher levels of type-2 biomarkers.
|Number of pages||11|
|Journal||The Journal of Allergy and Clinical Immunology: In Practice|
|Early online date||6 Oct 2021|
|Publication status||Published - 1 Feb 2022|